CO6862110A2 - Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos - Google Patents

Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos

Info

Publication number
CO6862110A2
CO6862110A2 CO14018361A CO14018361A CO6862110A2 CO 6862110 A2 CO6862110 A2 CO 6862110A2 CO 14018361 A CO14018361 A CO 14018361A CO 14018361 A CO14018361 A CO 14018361A CO 6862110 A2 CO6862110 A2 CO 6862110A2
Authority
CO
Colombia
Prior art keywords
paclitaxel
treatment
combination
gynecological cancers
erbb3 antibodies
Prior art date
Application number
CO14018361A
Other languages
English (en)
Inventor
William Kubasek
Victor Moyo
Joseph Pearlberg
Isabelle Bah-Fisch
Gavin Macbeath
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of CO6862110A2 publication Critical patent/CO6862110A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
CO14018361A 2011-06-30 2014-01-29 Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos CO6862110A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503342P 2011-06-30 2011-06-30
US201161529630P 2011-08-31 2011-08-31
FR1250860 2012-01-30

Publications (1)

Publication Number Publication Date
CO6862110A2 true CO6862110A2 (es) 2014-02-10

Family

ID=47424747

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14018361A CO6862110A2 (es) 2011-06-30 2014-01-29 Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos

Country Status (15)

Country Link
US (1) US20140248280A1 (es)
EP (1) EP2726100A4 (es)
JP (1) JP2014527035A (es)
KR (1) KR20140063578A (es)
CN (1) CN103945866A (es)
AU (1) AU2012275850A1 (es)
BR (1) BR112013033544A2 (es)
CA (1) CA2839869A1 (es)
CO (1) CO6862110A2 (es)
EA (1) EA201490180A1 (es)
MA (1) MA35281B1 (es)
MX (1) MX2013015333A (es)
TW (1) TW201317002A (es)
UY (1) UY34178A (es)
WO (1) WO2013003037A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CN104755499B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
JP6755235B2 (ja) * 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害
AU2016248329A1 (en) * 2015-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3429623A1 (en) 2016-03-15 2019-01-23 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073629A2 (en) * 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
ES2431940T3 (es) * 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
NZ602084A (en) * 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers

Also Published As

Publication number Publication date
TW201317002A (zh) 2013-05-01
KR20140063578A (ko) 2014-05-27
CN103945866A (zh) 2014-07-23
WO2013003037A2 (en) 2013-01-03
AU2012275850A1 (en) 2013-03-21
MA35281B1 (fr) 2014-07-03
EA201490180A1 (ru) 2014-08-29
CA2839869A1 (en) 2013-01-03
US20140248280A1 (en) 2014-09-04
JP2014527035A (ja) 2014-10-09
EP2726100A4 (en) 2015-04-29
BR112013033544A2 (pt) 2017-12-19
MX2013015333A (es) 2014-07-09
UY34178A (es) 2013-01-31
WO2013003037A3 (en) 2014-05-01
EP2726100A2 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
CO6821893A2 (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CO6862110A2 (es) Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
CO6821964A2 (es) Compuestos para el tratamiento de la adicción
BR112014007603A2 (pt) métodos de tratamento do câncer
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
DK2707030T3 (da) Cancerbehandlinger
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
HK1222869A1 (zh) 用於治療癌症的針對 的偶聯抗體
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
FI20116306A (fi) Teroitin
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
HK1225967A1 (zh) IFN-γ與抗-ERBB抗體的結合物用於治療癌症
FR2971576B1 (fr) Ballon eclairant
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
HK1204629A1 (en) Treatment of mucositis with immunoglobulin
DK3329927T3 (da) IBS-behandling med probiotika
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
IS9035A (is) Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
BR112014028306A2 (pt) métodos para tratamento de câncer gástrico.
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
FI20126009A (fi) Sektoriloisto
ZA201504169B (en) Anti-adam28 antibody for treating cancer
ES1076161Y (es) Revestimiento integral para el interior de automoviles.

Legal Events

Date Code Title Description
FA Application withdrawn